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Short title: Cancer mortality in selected Australasian countries and Russia 
 
Key message: Total cancer mortality in Russia and Australasia is predicted to decline persistently until 2018. 
Lung cancer trends in men were favourable, with stronger falls in the 25-44 years age-group, but remained 
exceedingly high in Russian men. Between 1993 and 2018 about 1 million cancer deaths were avoided in 
Russia and 650,000 in Japan. 
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Abstract 
Background: Predicted cancer mortality figures and rates are useful for public health planning. 
Materials and Methods: We retrieved cancer death certification data from 10 major cancer sites and total 
cancers from the World Health Organisation (WHO) database and population data from WHO and United 
Nations Population Division databases. We obtained figures for Russia, Israel, Hong Kong, Japan, the 
Philippines, Korea, and Australia in 1970-2015. We predicted numbers of deaths by age-group and age-
standardized rates (world population) for 2018 by applying a linear regression to mortality data of each age-
group over the most recent trend segment identified by a joinpoint regression model. 
Results: Russia had the highest predicted total cancer mortality rates, 158.5/100,000 men and 84.1/100,000 
women. Men in the Philippines showed the lowest rates for 2018 (84.6/100,000) and Korean males the most 
favourable predicted fall (21% between 2018 and 2012). Women in Korea had the lowest total cancer 
predicted rate (52.5/100,000). Between 1993 and 2018, i.e. by applying the 1993 rates to populations in 
subsequent years, a substantial number of cancer deaths was avoided in Russia (1,000,000 deaths, 821,000 
in men and 179,000 in women), Israel (40,000 deaths, 21,000 in men and 19,000 in women), Hong Kong 
(63,000 deaths, 40,000 in men and 23,000 in women), Japan (651,000 deaths, 473,000 in men and 178,000 
in women), Korea (327,000 deaths, 250,000 in men and 77,000 in women) and the Australia (181,000 deaths, 
125,000 in men and 56,000 in women). No appreciable reduction in cancer deaths was found in the 
Philippines. 
Conclusion: Overall, we predicted falls in cancer mortality. However, these are less marked and later 
compared to the EU and USA. Substantial numbers of deaths were averted in all countries considered except 
the Philippines underlining the need for improvement in cancer prevention and management. 
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Introduction 
Since 2011, we published cancer mortality predictions for the European Union (EU) as a whole and its largest 
countries [1, 2] on the basis of the World Health Organization (WHO) mortality database. We also produced 
prediction estimates for 2017 for the most populous Latin American countries [3]. Thus, in this paper we 
considered major countries for which we had good quality data: we predicted the number of cancer deaths 
and mortality rates for 2018 for the Russian Federation and six Australasian countries, focusing on lung 
cancer. 
 
Materials and methods 
We obtained death certification data from the WHO database [4] for the Russian Federation and selected 
Australasian countries with over 7 million inhabitants and over 90% death certification coverage (i.e., Israel, 
Hong Kong SAR, Japan, the Philippines, the Republic of Korea, and Australia) in the period between 1970 and 
2015 (up to 2011 for the Philippines, 2013 for Russia, and 2014 for Israel). Cancer deaths were recoded 
according to the 10th International Classification of Diseases Revision [5]. We considered cancer of the 
stomach, colorectum, pancreas, lung, breast, uterus (cervix and corpus), ovary, prostate, bladder, leukaemias 
and total neoplasms (malignant and benign). 
We retrieved resident population figures from the same WHO database and, when necessary, due to lack of 
data, from the United Nations (UN) Population Division database [4, 6]. 
We used certified deaths and resident population matrices to calculate age-specific death rates for each 5-
year age-group (from 0-4 to 85+ years), sex and calendar year. We also calculated yearly and quinquennial 
age-standardized rates per 100,000 person-years (direct method, world standard population) at all ages and, 
for lung cancer, also at the truncated 25-44, 45-64, 65-74, and 75+ age-groups. 
We computed predicted age-specific estimates of certified numbers of deaths for 2018 and the 
corresponding 95% prediction intervals (PIs) by fitting a logarithmic Poisson count data joinpoint regression 
model to the number of certified deaths in each 5-year age-group [7]. We applied a linear regression to 
mortality data of each age-group over the most recent trend segment identified by the joinpoint model to 
obtain the prediction estimates. We predicted age-standardized death rates with their corresponding 95% 
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PIs using the predicted age-specific death counts and the predicted population data from the UN database 
[6]. 
Numbers of avoided cancer deaths over the 25 years from 1993 to 2018 were estimated by comparing 
observed deaths and expected ones on the basis of the 1993 age-specific rate (total cancer mortality peak 
rate for most considered countries). 
 
Results 
Figure 1 displays bar plots of age-standardized mortality rates per 100,000 person-years for all neoplasms in 
the studied countries, in men and women separately, in 2012 (dark grey) and predicted rates for 2018 (light 
grey). We predicted favourable total cancer mortality trends for all countries; men showed more marked 
declines. 
Table 1 (men), and table 2 (women), show numbers of cancer deaths and age-standardized rates observed 
in 2012, along with predicted figures for 2018; they include 95% PIs and percent differences between 2018 
and 2012 age-standardized rates. In men, Russia showed the highest total cancer mortality rates, with values 
of 167.8/100,000 in 2012 and 158.5 in 2018 (-5.6%). The most favourable predicted trend in all cancers rates 
was in Korean men, reaching a rate of 108.9 in 2018; however, the number of deaths is predicted to increase. 
Appreciable declines (around 13-15%) were predicted in Hong Kong, Japan, and Australia. Israel and the 
Philippines had the lowest predicted rates around 95 and 85/100,000, respectively. The Philippines showed 
the largest increase in terms of numbers of deaths (+16.8%). Russian women had the highest predicted total 
cancer mortality (84.1/100,000), Korean women had the lowest one, 52.5/100,000, and they also showed 
the largest fall in rates. 
Figure 2 shows trends in total cancer mortality rates, from 1970-1974 to 2010-2014, in men and women 
separately, and predicted rates for 2018. In males, declines in rates started around 2000, except for Hong 
Kong and Australia, where rates started to fall earlier. In women trends started to decline around 1990 or 
earlier (Hong Kong). Rates in Japan declined over the whole period, while the Philippines had a rising trend 
up to 2000 and then levelled off. 
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Figure 3 displays mortality trends for the studied cancer sites by country and sex. In men, lung cancer rates 
in Russia were the highest over the studied period. Stomach cancer trends declined over the whole period 
and colorectal cancer trends have been increasing up to around 2000, to level off or decrease thereafter. 
Russia and Hong Kong showed upwards prostate cancer trends. In Israel lung, colorectal and prostate trends 
showed a peak around 2000s. Japan and Korea showed strong declines in stomach cancer rates (they had 
the highest ones in the 1970-80s). Overall, men in all countries had stable or slightly increasing patterns for 
pancreas and bladder. In Russia, rates for breast and colorectal cancers are predicted to decline. In Japan the 
lung cancer in women tended to increase up to 2000s to then decline; breast cancer rates rose over the 
whole period to then flatten in recent years. The highest female mortality rates in the Philippines were for 
breast cancer and uterus. Australia had strong downward breast and colorectal cancer trends. 
Table 3 shows age-standardized mortality rates for lung cancer at all ages and at 25-44, 45-64, 65-74, and 
75+ years age-groups, in 2005-2009 and 2010-2014, including predicted rates for 2018, the corresponding 
95% PIs, and the percent difference between 2018 and 2010-2014. Men and women presented favourable 
predicted patterns at all ages, with the exception of Hong Kong women (+0.4%); trends had stronger falls for 
the 25-44 age-group, but not for women from Israel, Japan, and the Philippines. Trends in women are less 
favourable. 
Figure 4 shows the estimated number of avoided cancer deaths in men and women between 1993 and 2018, 
assuming the age-specific rates in 1993 as constant (light grey area). Over the 25 years considered, a 
substantial number of cancer deaths was avoided in Russia (1,000,000 deaths, 821,000 in men and 179,000 
in women), Israel (40,000, 21,000 in men and 19,000 in women), Hong Kong (63,000, 40,000 in men and 
23,000 in women), Japan (651,000, 473,000 in men and 178,000 in women), Korea (327,000, 250,000 in men 
and 77,000 in women) and Australia (181,000, 125,000 in men and 56,000 in women). There was no 
appreciable reduction in cancer deaths in the Philippines. 
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Discussion 
Similarly to other areas of the world [8, 9], in Russia and the six Australasian studied countries, favourable 
trends for total cancer mortality are predicted to continue up to 2018 in both sexes. However, the number 
of cancer deaths is still increasing [10, 11]. Except Hong Kong and Australia, total cancer mortality started to 
decline about a decade later than the EU and the USA [9, 12]. 
In all countries (except Australia) lung cancer trends peaked in males between late 1990s and 2000s (later 
than in North America and most EU countries). Female lung cancer trends were favourable and particularly 
low in Russia as compared to the EU and North America, reflecting the low prevalence of smoking among 
Russian women [13]. The rise in lung cancer mortality rate for women aged 25-44 years in Israel is particularly 
worrisome. Hong Kong and Australia reached the highest rates in 2018 [2]. Thus, urgent measures on tobacco 
control are needed [14, 15]. 
Stomach cancer showed strong falls over the whole period up to 2018 for all countries and both sexes; 
however, in Russia, Japan and Korea, rates were about double than in the EU or other high-income countries 
[9, 16]. In the other selected countries, rates over last years were very low and closer to North American ones 
(around 3/100,000 men and 2/100,000 women) [8]. The fall in gastric cancer rates is related to both a 
declining prevalence of Helicobacter pylori and improvements in diet and food conservation over the period 
[17]. 
Trends from colorectal cancer started to decline around 2000 or later (Russia and Korea), i.e. later than most 
high-income countries [8, 9]. The falls in colorectal cancer mortality are largely due to earlier diagnosis – 
including, in selected areas, population screening – the removal of adenomas and treatments [18]; the later 
onset of declines suggests delays in colorectal cancer management in several of the countries considered, in 
any case acceptable information on national screening programs in the considered countries is not available 
[19]. However, rates remain comparatively low in Japan, Korea and other Asian countries. Also, use of aspirin 
may have favourably influenced colorectal cancer trends [20]. 
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Pancreatic cancer mortality showed unfavourable patterns in most countries considered, for both sexes. 
Predicted rates were similar to the EU and higher than Latin America [3, 21]. Smoking is the main known risk 
factor for pancreatic cancer. Under-certification remains possible. 
Russia and Israel showed similar breast cancer mortality rates to the EU and North America [3, 8]. The falls 
in breast cancer rates are largely due to improved management and diagnosis; national screening and cancer 
control programs are only available in selected countries (i.e. Israel) [19]: their widespread adoption could 
lead to improvements in breast cancer rates in several of the considered countries [22, 23]. 
Except for Russia and the Philippines, uterine cancer trends declined, similarly to the EU and USA. We were 
unable to distinguish between cervical and corpus uteri cancer from death certification data. However, since 
in some of the largest countries considered (cervix) uterus remains a major cause of cancer deaths it is 
worthwhile investigating in spite of this limitation. Most declines in (cervix) uterus cancer rates worldwide 
were due to screening [24, 25]. The limited declines in some of the studied countries indicate the urgent 
need to adopt modern population-based cervical screening programs. 
Ovarian cancer mortality declines in the considered countries are mainly due to the widespread use of oral 
contraceptives (OCs) in generations born after 1930 [26-28]. Declines were smaller than in North America 
and Northern Europe [29] because OCs where used less frequently and later in Russia, Japan, Korea, 
explaining the less favourable predictions. 
Recent falls in prostate cancer mortality registered in North America and in the EU are due to early diagnosis 
and mainly improved treatment [30], predictions for Australia were similar. The absence of such favourable 
trends in Russia suggests delays in prostate cancer management. 
Bladder cancer predictions were favourable for both sexes, as in other areas of the world [9]. For men this 
reflects the declining exposure to occupational bladder carcinogens and mostly the declining prevalence of 
tobacco smoking. The favourable prediction for women may reflect an improved control of chronic cystitis 
[31]. Better disease management may have favourably affected trends [32]. 
Predictions for leukaemias were favourable in all countries considered, reflecting the improved disease 
treatment [33, 34]. 
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We considered countries with relatively large population sizes, and good death certification coverage, thus 
our projection methods should not be appreciably affected by random oscillations; however, caution should 
be exercised when interpreting results, which in any case indicate a substantial number of cancer death 
avoided over the last 25 years in all countries considered, except the Philippines. 
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Figure legends 
Figure 1. Bar-plots of age-standardized (world population) death rates per 100,000 person-years for the year 
2012 (dark grey) and predicted rates for 2018 (light grey) for total cancer in Russia and six selected 
Australasian countries, men and women. 
Figure 2. Age-standardized (world population) total cancer mortality rate trends in quinquennia from 1970 
to 2014 and predicted rates for 2018 with 95% prediction intervals (PIs), for Russia (diamonds), Israel (circles), 
Hong Kong (squares), Japan (triangles), the Philippines (crosses), Korea (xs), and Australia (inverted triangles), 
in men and women. 
Figure 3. Age-standardized (world population) cancer mortality rate trends in quinquennia from 1970 to 2014 
and predicted rates for 2018 with 95% prediction intervals (PIs) for Russia and the six Australasian countries. 
Men: stomach (squares), colorectum (circles), pancreas (triangles), lung (crosses), prostate (ticked squares), 
bladder (asterisks) and leukaemias (ticked diamonds). Women: stomach (squares), colorectum (circles), 
pancreas (triangles), lung (crosses), breast (xs), uterus (cervix and corpus) (diamonds), ovary (inverted 
triangles), bladder (asterisks) and leukaemias (ticked diamonds). 
Figure 4. Total avoided cancer deaths for 6 out of the 7 countries considered, men and women, between the 
rate in 1993 and 2018 (light grey area); observed numbers of cancer deaths from 1993 to 2015 (or the latest 
available year) and predicted cancer deaths from 2015 to 2018 (black line); estimated numbers of total cancer 
deaths by applying 1993 age-specific mortality rate (dark grey line). During the 25 years period a total of over 
2,200,000 cancer deaths have been avoided in 6 of the 7 countries considered (1,700,000 in men and 500,000 
in women). No reduction in cancer deaths was registered in the Philippines. In 2018 alone about 174,000 
deaths are predicted to be avoided in men, and about 57,000 in women. Abbreviation: ASR, age-specific rate.  
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Table 1. Number of predicted deaths and mortality rates per 100,000 men for the year 2018 and 
comparison figures for the year 2012 (2011 for Philippines), from Russia and selected Australasian 
countries, with 95% prediction intervals and percent differences between 2018 and 2012 rates. 
 
 
Observed 
number 
of deaths 
2012 
Predicted 
number 
of deaths 
2018 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
Observed 
ASR* 
2012 
Predicted 
ASR* 
2018 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
% 
difference 
2018 
versus 
2012 
Russian Federation STOMACH 18314 13840 11861 15821 19.65 13.57 11.37 15.77 -30.9 
COLORECTUM 17368 17890 15790 19991 18.44 17.62 15.30 19.94 -4.4 
PANCREAS 8208 9140 8323 9963 8.91 9.16 8.27 10.06 2.8 
LUNG 41041 40240 35980 44497 44.52 39.72 35.14 44.30 -10.8 
PROSTATE 10860 12030 10574 13489 11.40 11.71 10.11 13.32 2.8 
BLADDER 5174 4520 3917 5131 5.39 4.43 3.77 5.08 -17.8 
LEUKAEMIAS 3477 3380 3024 3733 4.09 3.73 3.34 4.11 -8.9 
ALL CANCERS 154550 158950 143103 174795 167.79 158.46 141.21 175.71 -5.6 
Israel STOMACH 294 300 259 339 5.62 4.89 4.24 5.53 -13.1 
COLORECTUM 725 730 652 818 12.93 11.39 10.04 12.74 -11.9 
PANCREAS 471 530 479 582 9.28 9.01 8.05 9.97 -2.9 
LUNG 1178 1400 1307 1497 23.73 24.14 22.39 25.89 1.7 
PROSTATE 417 370 315 423 6.43 4.71 4.00 5.42 -26.8 
BLADDER 264 320 276 366 4.33 4.23 3.64 4.83 -2.3 
LEUKAEMIAS 275 300 269 332 5.21 4.86 4.28 5.43 -6.8 
ALL CANCERS 5525 5910 5562 6256 104.19 95.15 88.82 101.49 -8.7 
Hong Kong SAR STOMACH 379 380 328 424 5.37 4.42 3.76 5.08 -17.8 
COLORECTUM 1110 1210 1112 1298 15.58 13.99 12.80 15.17 -10.2 
PANCREAS 287 340 312 376 4.41 4.59 4.12 5.05 4.1 
LUNG 2597 2670 2498 2848 37.56 31.55 29.10 34.00 -16.0 
PROSTATE 362 400 351 452 4.39 3.83 3.29 4.36 -12.9 
BLADDER 132 120 97 147 1.61 1.15 0.85 1.45 -28.4 
LEUKAEMIAS 181 170 143 193 3.04 2.37 1.69 3.06 -22.0 
ALL CANCERS 8342 8840 8448 9234 125.49 108.14 102.53 113.74 -13.8 
Japan STOMACH 32206 29450 28711 30188 17.65 12.94 12.37 13.52 -26.7 
COLORECTUM 26870 29740 28841 30645 15.48 14.94 14.30 15.57 -3.5 
PANCREAS 15516 17090 16559 17619 9.16 8.67 8.37 8.97 -5.4 
LUNG 51371 54230 53242 55223 27.40 24.73 24.01 25.46 -9.7 
PROSTATE 11143 11780 11290 12262 4.78 4.18 4.02 4.34 -12.7 
BLADDER 5002 6060 5857 6256 2.37 2.40 2.29 2.51 1.3 
LEUKAEMIAS 4779 4830 4591 5078 3.34 2.62 2.40 2.85 -21.5 
ALL CANCERS 220971 226450 222331 230559 123.21 104.86 101.83 107.88 -14.9 
Philippines STOMACH 786 780 708 858 2.67 2.10 1.91 2.30 -21.2 
COLORECTUM 3150 3720 3578 3866 10.58 9.71 9.32 10.11 -8.2 
PANCREAS 684 830 781 878 2.21 2.16 2.03 2.29 -2.5 
LUNG 5969 6550 6241 6860 20.60 17.89 17.04 18.75 -13.2 
PROSTATE 2467 3070 2882 3256 10.79 9.98 9.38 10.57 -7.5 
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Observed 
number 
of deaths 
2012 
Predicted 
number 
of deaths 
2018 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
Observed 
ASR* 
2012 
Predicted 
ASR* 
2018 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
% 
difference 
2018 
versus 
2012 
BLADDER 223 280 245 310 0.84 0.78 0.69 0.87 -7.1 
LEUKAEMIAS 1445 1620 1530 1715 3.56 3.45 3.25 3.65 -3.1 
ALL CANCERS 27616 32260 31608 32906 91.35 84.55 82.79 86.30 -7.4 
Republic of Korea STOMACH 6090 5050 4832 5276 17.55 10.61 10.06 11.16 -39.6 
COLORECTUM 4961 5230 4941 5514 14.59 11.25 10.61 11.88 -22.9 
PANCREAS 2616 3120 2977 3264 7.57 6.77 6.45 7.08 -10.6 
LUNG 12175 13700 13275 14130 35.06 28.58 27.65 29.50 -18.5 
PROSTATE 1460 1920 1839 2009 4.53 4.00 3.81 4.18 -11.8 
BLADDER 918 1080 1001 1165 2.79 2.29 2.12 2.45 -17.9 
LEUKAEMIAS 919 920 841 1005 3.18 2.21 1.92 2.51 -30.3 
ALL CANCERS 47228 50720 49353 52095 138.08 108.91 105.79 112.04 -21.1 
Australia STOMACH 707 680 618 750 3.48 2.85 2.55 3.14 -18.3 
COLORECTUM 2958 2840 2669 3001 13.94 11.39 10.76 12.01 -18.3 
PANCREAS 1331 1410 1323 1497 6.48 5.84 5.44 6.25 -9.8 
LUNG 4883 4970 4779 5158 23.22 19.74 18.95 20.53 -15.0 
PROSTATE 3078 3020 2842 3199 11.94 9.39 8.88 9.91 -21.3 
BLADDER 707 730 655 806 2.96 2.42 2.17 2.67 -18.2 
LEUKAEMIAS 943 930 849 1005 4.58 3.48 3.12 3.84 -23.9 
ALL CANCERS 24596 25990 25335 26648 115.50 101.08 98.60 103.57 -12.5 
*ASR, age-standardized mortality rates using the World Standard Population. 
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Table 2. Number of predicted deaths and mortality rates per 100,000 women for the year 2018 and 
comparison figures for the year 2012 (2011 for Philippines), from Russia and selected Australasian 
countries, with 95% prediction intervals and percent differences between 2018 and 2012 rates. 
 
 
Observed 
number 
of deaths 
2012 
Predicted 
number 
of deaths 
2018 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
Observed 
ASR* 
2012 
Predicted 
ASR* 
2018 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
% 
difference 
2018 
versus 
2012 
Russian Federation STOMACH 13610 10920 9372 12465 8.03 5.84 4.86 6.83 -27.2 
COLORECTUM 21388 21010 19131 22892 12.18 11.12 9.93 12.31 -8.7 
PANCREAS 7969 7920 7136 8698 4.70 4.43 3.93 4.93 -5.8 
LUNG 8839 8890 8101 9683 5.47 5.34 4.84 5.84 -2.4 
BREAST 22932 21000 18849 23154 15.90 13.20 11.81 14.58 -17.0 
UTERUS (CERVIX AND CORPUS) 12922 14180 12958 15406 9.62 10.24 9.46 11.03 6.5 
OVARY 7788 7290 6526 8056 5.61 5.16 4.62 5.70 -7.9 
BLADDER 1413 1290 1124 1450 0.70 0.62 0.53 0.70 -12.3 
LEUKAEMIAS 3553 3140 2767 3503 2.65 2.09 1.82 2.36 -21.2 
ALL CANCERS 136246 137810 124794 150834 88.60 84.08 75.84 92.33 -5.1 
Israel STOMACH 199 190 158 224 3.06 2.55 2.07 3.02 -16.8 
COLORECTUM 705 670 604 737 9.36 8.02 7.13 8.91 -14.3 
PANCREAS 401 460 417 499 5.65 5.80 5.27 6.32 2.7 
LUNG 583 650 593 705 9.44 9.02 8.28 9.76 -4.4 
BREAST 994 1000 923 1087 16.81 13.96 12.65 15.27 -17.0 
UTERUS (CERVIX AND CORPUS) 248 340 293 381 4.14 4.43 3.83 5.02 6.9 
OVARY 302 330 289 361 5.21 4.88 4.27 5.48 -6.5 
BLADDER 85 100 79 112 1.01 0.97 0.76 1.17 -4.3 
LEUKAEMIAS 245 240 214 272 3.59 3.11 2.66 3.57 -13.4 
ALL CANCERS 5382 5890 5679 6110 81.37 76.49 73.34 79.64 -6.0 
Hong Kong SAR STOMACH 278 260 217 294 3.20 2.43 1.98 2.88 -24.3 
COLORECTUM 854 1020 949 1100 9.55 9.32 8.53 10.12 -2.3 
PANCREAS 251 300 269 327 3.15 3.19 2.88 3.51 1.3 
LUNG 1296 1530 1422 1633 15.56 15.41 14.11 16.71 -0.9 
BREAST 601 680 632 736 8.58 8.68 7.95 9.41 1.1 
UTERUS (CERVIX AND CORPUS) 250 300 270 335 3.49 3.74 3.31 4.18 7.3 
OVARY 176 220 190 244 2.47 2.82 2.44 3.20 14.5 
BLADDER 52 50 29 69 0.49 0.34 0.17 0.51 -31.4 
LEUKAEMIAS 95 150 120 178 1.53 1.80 1.13 2.48 18.0 
ALL CANCERS 5609 6570 6350 6782 69.72 68.25 65.56 70.94 -2.1 
Japan STOMACH 16922 15310 14779 15848 6.67 4.80 4.53 5.08 -28.0 
COLORECTUM 22768 24900 24410 25390 8.97 8.60 8.34 8.86 -4.2 
PANCREAS 14399 16380 15836 16933 5.76 5.48 5.24 5.72 -4.9 
LUNG 20145 22290 21790 22790 7.76 7.22 6.93 7.51 -7.0 
BREAST 12527 13680 13296 14072 8.67 8.49 8.16 8.82 -2.1 
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Lower 
prediction 
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2012 
Predicted 
ASR* 
2018 
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prediction 
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limit 
(95%) 
% 
difference 
2018 
versus 
2012 
UTERUS (CERVIX AND CORPUS) 6113 6450 6189 6719 4.01 4.19 3.94 4.43 4.3 
OVARY 4790 4710 4511 4904 3.24 2.78 2.61 2.95 -14.2 
BLADDER 2296 2590 2478 2712 0.65 0.59 0.55 0.63 -9.3 
LEUKAEMIAS 3121 3350 3171 3520 1.89 1.40 1.25 1.56 -25.9 
ALL CANCERS 151234 161290 159185 163403 66.05 60.28 58.87 61.68 -8.7 
Philippines STOMACH 604 560 504 624 1.69 1.25 1.12 1.38 -26.3 
COLORECTUM 2580 3050 2921 3184 7.27 6.73 6.43 7.02 -7.5 
PANCREAS 693 830 780 883 1.95 1.84 1.73 1.96 -5.3 
LUNG 2389 2840 2727 2959 6.72 6.30 6.03 6.56 -6.4 
BREAST 6162 7540 7299 7775 16.34 16.03 15.52 16.55 -1.9 
UTERUS (CERVIX AND CORPUS) 2895 3500 3333 3671 7.56 7.43 7.06 7.80 -1.7 
OVARY 1360 1680 1592 1761 3.59 3.56 3.38 3.73 -0.8 
BLADDER 113 130 102 150 0.33 0.28 0.23 0.34 -15.5 
LEUKAEMIAS 1354 1600 1517 1681 3.17 3.20 3.03 3.37 0.8 
ALL CANCERS 26667 32510 31871 33141 71.57 69.99 68.57 71.41 -2.2 
Republic of Korea STOMACH 3252 2640 2461 2818 6.53 3.96 3.58 4.35 -39.3 
COLORECTUM 3667 4050 3856 4235 7.15 5.94 5.58 6.29 -16.9 
PANCREAS 2162 2760 2645 2874 4.38 4.46 4.27 4.65 1.8 
LUNG 4479 5110 4925 5293 8.89 7.85 7.55 8.15 -11.7 
BREAST 1993 2490 2364 2615 5.05 5.58 5.27 5.90 10.5 
UTERUS (CERVIX AND CORPUS) 1219 1330 1232 1429 2.80 2.65 2.44 2.86 -5.3 
OVARY 940 1120 1053 1196 2.26 2.21 2.04 2.37 -2.4 
BLADDER 303 360 316 409 0.50 0.46 0.40 0.52 -7.1 
LEUKAEMIAS 747 680 612 743 2.21 1.32 1.06 1.58 -40.5 
ALL CANCERS 27915 31740 30952 32522 59.28 52.54 50.99 54.10 -11.4 
Australia STOMACH 436 400 354 451 1.66 1.40 1.20 1.61 -15.2 
COLORECTUM 2462 2490 2352 2631 9.28 8.00 7.56 8.45 -13.8 
PANCREAS 1193 1330 1236 1420 4.64 4.55 4.25 4.86 -1.9 
LUNG 3255 3600 3471 3726 14.10 13.65 13.14 14.15 -3.2 
BREAST 2795 2900 2756 3039 13.21 11.68 11.10 12.26 -11.6 
UTERUS (CERVIX AND CORPUS) 646 720 661 773 2.98 2.91 2.65 3.18 -2.3 
OVARY 942 980 889 1062 4.15 3.74 3.38 4.11 -9.9 
BLADDER 331 290 245 331 1.02 0.76 0.64 0.88 -25.7 
LEUKAEMIAS 683 730 679 786 2.95 2.36 2.10 2.63 -19.7 
ALL CANCERS 18957 21250 20846 21645 78.36 74.68 73.37 75.99 -4.7 
*ASR, age-standardized mortality rates using the World Standard Population. 
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Table 3. Age-standardized lung cancer mortality rates in quinquennia 2005-2009 and 2010-2014 and predicted rates for 2018 for all ages, 25-44, 
45-64, 65-74, 75+ years age-groups in Russia and different selected Australasian countries, in men and women, with corresponding percent 
changes. 
 
 
Men  Women 
ASR* 
2005-2009 
ASR* 
2010-2014 
Predicted 
ASR 
2018* 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
% difference 
(2018/2010-14) 
 
ASR* 
2005-2009 
ASR* 
2010-2014 
Predicted 
ASR 
2018* 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
% difference 
(2018/2010-14) 
Russian 
Federation 
All ages 50.11 45.54 39.72 35.14 44.30 -12.8  5.51 5.52 5.34 4.84 5.84 -3.2 
Truncated 25-44 years 4.51 4.02 1.86 1.13 2.59 -53.7  1.13 1.28 1.14 0.93 1.35 -10.8 
Truncated 45-64 years 120.92 115.60 120.66 113.15 128.18 4.4  12.50 12.92 13.78 12.54 15.01 6.6 
Truncated 65-74 years 376.21 327.16 191.63 105.79 277.47 -41.4  34.98 33.93 29.60 21.26 37.94 -12.8 
Truncated 75+ years 352.31 303.93 334.64 299.17 370.12 10.1  53.24 50.20 46.19 40.25 52.13 -8.0 
Israel All ages 25.19 24.71 24.14 22.39 25.89 -2.3  8.99 9.71 9.02 8.28 9.76 -7.1 
Truncated 25-44 years 1.84 1.78 1.63 0.73 2.54 -8.2  1.22 0.91 1.16 0.56 1.76 27.3 
Truncated 45-64 years 51.10 48.60 50.10 45.27 54.93 3.1  18.18 20.36 17.21 14.49 19.92 -15.5 
Truncated 65-74 years 189.83 182.55 159.56 131.44 187.67 -12.6  57.95 62.72 60.95 53.98 67.91 -2.8 
Truncated 75+ years 273.50 292.00 309.53 288.90 330.16 6.0  115.58 122.52 120.20 101.65 138.76 -1.9 
Hong Kong SAR All ages 42.16 36.45 31.55 29.10 34.00 -13.4  16.09 15.36 15.41 14.11 16.71 0.4 
Truncated 25-44 years 4.15 2.93 2.16 0.29 4.03 -26.2  2.39 2.44 2.38 1.48 3.28 -2.5 
Truncated 45-64 years 71.11 61.28 55.17 48.64 61.70 -10.0  27.22 29.53 31.96 29.12 34.80 8.2 
Truncated 65-74 years 295.67 256.04 191.90 153.90 229.90 -25.1  96.94 88.70 82.23 59.94 104.52 -7.3 
Truncated 75+ years 637.50 560.04 545.44 505.94 584.93 -2.6  270.88 232.86 229.80 214.12 245.49 -1.3 
Japan All ages 28.87 27.39 24.73 24.01 25.46 -9.7  7.95 7.79 7.22 6.93 7.51 -7.3 
Truncated 25-44 years 1.95 1.56 1.41 1.13 1.70 -9.4  1.07 0.87 0.88 0.71 1.05 1.5 
Truncated 45-64 years 42.51 38.73 28.24 24.99 31.49 -27.1  13.69 12.72 8.98 7.66 10.31 -29.4 
Truncated 65-74 years 190.09 191.79 207.20 200.27 214.13 8.0  48.81 50.81 55.66 53.25 58.06 9.5 
Truncated 75+ years 537.16 500.05 431.52 424.67 438.37 -13.7  130.85 129.44 124.70 121.73 127.67 -3.7 
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Men  Women 
ASR* 
2005-2009 
ASR* 
2010-2014 
Predicted 
ASR 
2018* 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
% difference 
(2018/2010-14) 
 
ASR* 
2005-2009 
ASR* 
2010-2014 
Predicted 
ASR 
2018* 
Lower 
prediction 
limit 
(95%) 
Upper 
prediction 
limit 
(95%) 
% difference 
(2018/2010-14) 
Philippines All ages 23.01 20.91 17.89 17.04 18.75 -14.4  6.92 6.81 6.30 6.03 6.56 -7.5 
Truncated 25-44 years 2.63 2.63 2.31 1.99 2.63 -12.2  1.58 1.39 1.50 1.27 1.72 7.6 
Truncated 45-64 years 50.00 42.56 33.95 31.38 36.51 -20.2  14.46 14.51 13.33 12.57 14.09 -8.1 
Truncated 65-74 years 169.94 160.53 142.65 129.85 155.44 -11.1  45.08 44.58 39.94 36.22 43.66 -10.4 
Truncated 75+ years 210.95 199.78 181.65 167.86 195.45 -9.1  72.44 70.10 66.69 61.47 71.90 -4.9 
Republic of Korea All ages 39.44 34.71 28.58 27.65 29.50 -17.7  9.46 8.87 7.85 7.55 8.15 -11.5 
Truncated 25-44 years 1.67 1.53 1.03 0.57 1.49 -32.7  1.34 1.17 0.88 0.50 1.27 -24.4 
Truncated 45-64 years 52.38 42.20 32.93 31.41 34.45 -22.0  14.38 13.73 12.64 11.89 13.39 -7.9 
Truncated 65-74 years 320.75 266.73 216.39 202.24 230.54 -18.9  61.53 53.86 46.41 42.72 50.10 -13.8 
Truncated 75+ years 648.67 646.71 561.62 536.39 586.85 -13.2  164.04 162.34 144.94 137.47 152.42 -10.7 
Australia All ages 26.37 23.51 19.74 18.95 20.53 -16.0  14.16 13.96 13.65 13.14 14.15 -2.2 
Truncated 25-44 years 1.62 1.33 1.31 0.82 1.81 -1.1  1.46 1.10 0.92 0.61 1.23 -16.3 
Truncated 45-64 years 42.85 37.16 30.92 28.65 33.20 -16.8  28.13 26.60 27.49 25.56 29.42 3.4 
Truncated 65-74 years 198.27 176.39 153.35 142.55 164.16 -13.1  101.12 104.26 101.18 96.15 106.22 -3.0 
Truncated 75+ years 392.79 362.63 292.14 274.53 309.74 -19.4  167.77 169.09 155.82 144.44 167.19 -7.8 
*ASR, age-standardized mortality rates using the World Standard Population. 
 
 
